Fatty Liver Disease (NAFLD & MASH): The Silent Epidemic Your Doctor May Already Be Watching
It has no symptoms in the early stages. It affects one in four adults worldwide. And right now, clinical research is racing to find the first FDA-approved treatments.
You may have heard your doctor mention an abnormal liver enzyme on a blood test — an elevated ALT or AST — and told you to reduce alcohol intake or lose weight. What your doctor may also be watching carefully is whether that abnormal result is the first sign of a condition called NAFLD: Non-Alcoholic Fatty Liver Disease.
NAFLD affects approximately 100 million Americans. For many, it stays relatively mild. But for a significant subset, it progresses to MASH — Metabolic Dysfunction-Associated Steatohepatitis — a more serious form of liver inflammation that can lead to cirrhosis, liver failure, or liver cancer.
NAFLD affects approximately 100 million Americans. For many, it stays relatively mild. But for a significant subset, it progresses to MASH — Metabolic Dysfunction-Associated Steatohepatitis — a more serious form of liver inflammation that can lead to cirrhosis, liver failure, or liver cancer.
What Is the Difference Between NAFLD and MASH?
NAFLD is the umbrella term for excess fat accumulation in the liver in people who drink little or no alcohol. It exists on a spectrum:
- Simple steatosis (fatty liver): Fat accumulates in liver cells, but there is minimal inflammation. Many people remain here and never progress.
- MASH (formerly called NASH): The liver becomes inflamed. Liver cells begin to die. Scar tissue forms. This is where serious long-term risk begins.
- Advanced fibrosis and cirrhosis: Scarring progresses, liver function declines. At this stage, the damage may be irreversible.
Why NAFLD Is Directly Tied to Metabolic Health
NAFLD is not primarily a liver disease in isolation — it is a metabolic disease that happens to manifest in the liver. The same factors that drive Type 2 diabetes, obesity, and cardiovascular risk drive NAFLD:
- Insulin resistance — the liver is flooded with glucose it cannot properly process
- Excess visceral fat — fat stored around the organs rather than under the skin
- Dyslipidemia — abnormal triglyceride and cholesterol levels
- Chronic low-grade systemic inflammation
1 in 4 adults worldwide have NAFLD — yet most have no symptoms until the disease has already progressed significantly.
The Race for the First Approved MASH Treatments
Until very recently, there were no FDA-approved medications specifically for NAFLD or MASH. The only recommended treatments were lifestyle modification — diet, exercise, and weight loss — which, while effective, are difficult to sustain long-term.
That is changing rapidly. Several drug classes are now in late-stage clinical trials showing meaningful reductions in liver fat, inflammation, and fibrosis. The pharmaceutical sponsors leading some of this research — including companies like Novo Nordisk and others — are among Mission Research Institute’s study partners.
If you have been told you have an elevated liver enzyme, fatty liver on imaging, or a formal NAFLD or MASH diagnosis, you may be eligible for a clinical trial that gives you access to these investigational treatments now — years before they reach standard clinical practice.
That is changing rapidly. Several drug classes are now in late-stage clinical trials showing meaningful reductions in liver fat, inflammation, and fibrosis. The pharmaceutical sponsors leading some of this research — including companies like Novo Nordisk and others — are among Mission Research Institute’s study partners.
If you have been told you have an elevated liver enzyme, fatty liver on imaging, or a formal NAFLD or MASH diagnosis, you may be eligible for a clinical trial that gives you access to these investigational treatments now — years before they reach standard clinical practice.
How Do You Know If You Have NAFLD?
Many people are diagnosed incidentally — their doctor orders routine blood work and notices elevated liver enzymes, or an ultrasound performed for another reason reveals a bright, echogenic liver consistent with fat deposition. A formal diagnosis may involve a FibroScan (liver elastography), an MRI, or in some cases a liver biopsy.
If any of these apply to you, talk to your doctor — and ask about clinical research options.
If any of these apply to you, talk to your doctor — and ask about clinical research options.
NAFLD and MASH are now the leading causes of liver transplant in the United States. Clinical research is the fastest path to treatments that could change that trajectory.
